$ZURA News

ZURA BIO LTD (NASDAQ:ZURA) Q1 2026: Cash Runway Extended Through 2028 as Phase 2 Trials Advance

Zura Bio Q1 EPS $(0.22) Misses $(0.18) Estimate

Zura Bio Announces Separation From CFO Eric Hyllengren; Marlyn Mathew Named Principal Accounting And Principal Financial Officer

Zura Bio: Momentum Is Real, But TibuSHIELD Needs To Deliver

Zura Bio shares are trading lower after Oppenheimer lowered its price target on the stock from $16 to $15.

Zura Bio shares are trading lower after Oppenheimer lowered its price target on the stock from $16 to $15.

Oppenheimer Maintains Outperform on Zura Bio, Lowers Price Target to $15

Zura Bio Q4 EPS $(0.49) Misses $(0.22) Estimate

Zura Bio Says Design Of Its Ongoing Phase 2 TibuSURE Clinical Trial Evaluating Tibulizumab In SSc Accepted For Presentation At Systemic Sclerosis World Congress

Zura Bio Closes $144 M Public Offering, Including Full Underwriters' Option, With Shares Priced At $6.25 And Pre-Funded Warrants At $6.249.

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

Zura Bio Prices $125M Public Offering Of 18.2M Class A Ordinary Shares At $6.25 And 1.8M Pre-Funded Warrants At $6.249

Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

Zura Bio Limited Reveals Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants; No Size Disclosed

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

Wedbush Initiates Coverage On Zura Bio with Outperform Rating, Announces Price Target of $15

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit